MMWR

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®

Retrieved on: 
Thursday, February 29, 2024
ACIP, Person, MD, FDA, Food, Risk, VLA, Vaccination, MMWR, Food and Drug Administration, Family, Saint-Herblain, Disease, CDC, Chikungunya, Ageing, Euronext Paris, Vaccine

ACIP recommends IXCHIQ® for persons aged ≥18 years traveling to a country or territory where there is a chikungunya outbreak.

Key Points: 
  • ACIP recommends IXCHIQ® for persons aged ≥18 years traveling to a country or territory where there is a chikungunya outbreak.
  • ACIP also recommended chikungunya vaccination for laboratory workers with potential for exposure to CHIKV.
  • IXCHIQ offers advantages to travelers on vacation and visiting family and to people engaged in business ventures, missions, or laboratory duties.
  • We embrace the ACIP endorsement, marking IXCHIQ® as the only approved and recommended vaccine for the target population.

Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease

Retrieved on: 
Thursday, August 3, 2023
ACIP, U.S. Department of Defense Strategy for Operating in Cyberspace, Parent, Office of Inspector General, U.S. Department of Health and Human Services, Vaccines for Children Program, Morbidity and Mortality Weekly Report, CDC, Child, Committee, Vaccination, The Committee, VFC, RSV, Patient, Risk, MMWR, Ageing, Disease, FDA, Immunization, Vaccine, Adolescence, Sanofi, Nirsevimab

The Committee also voted unanimously 10 to 0 to recommend routine use of Beyfortus for children aged 8 to 19 months who are at increased risk of severe RSV disease and entering their second RSV season.

Key Points: 
  • The Committee also voted unanimously 10 to 0 to recommend routine use of Beyfortus for children aged 8 to 19 months who are at increased risk of severe RSV disease and entering their second RSV season.
  • Additionally, the ACIP voted unanimously 11 to 0 to include Beyfortus in the Vaccines for Children (VFC) program.
  • “Today, we have turned the corner on the threat of RSV to our youngest, most vulnerable population.
  • Once approved, routine use of Beyfortus would be included in the CDC’s Child and Adolescent Immunization Schedule.

Vaccination in pregnancy greatly reduces risk of severe illness and death from COVID-19, and protects babies up to 6 months after birth

Retrieved on: 
Monday, July 3, 2023
Vaccine, Infection, Pregnancy, Placenta, Life, Stillbirth, Vaccination, SARS-CoV-2, Fetus, Safety, COVID-19, World, Morbidity and Mortality Weekly Report, Maternal death, Antibody, Delta, Messenger, Intensive care medicine, Mother, CDC, Public health, Patient, Population, Risk, MMWR, Blood, Korea Disease Control and Prevention Agency, Pre-eclampsia, Miscarriage, Internal bleeding, Mortality, Infant, ICU, Ageing, Disease, Center, Health, Death, World Health Organization, Apgar, Dietary supplement, Birth control, Omicron

From the early days of the pandemic, it has been evident that a COVID-19 infection in pregnancy can be serious.

Key Points: 
  • From the early days of the pandemic, it has been evident that a COVID-19 infection in pregnancy can be serious.
  • The data is stark: there is a five times higher risk of ICU admission and 22 times higher risk of maternal mortality due to COVID-19 infections in pregnancy.

Safety of COVID-19 vaccines in pregnancy

    • Despite the overwhelming data on the risks of COVID-19 infection in pregnancy, many have still been reluctant to get vaccinated, citing safety concerns.
    • We now have extensive evidence that shows COVID-19 vaccinations in pregnancy are safe, when given at any time during the pregnancy.

Infants protected by transfer of antibodies across placenta

    • Recent studies have shown that these IgG antibodies transferred to the fetus can remain in the baby for several months after birth.
    • One study showed 57 per cent of infants born to vaccinated mothers had detectable antibodies at six months.
    • Children younger than six months have the highest risk for severe outcomes associated with COVID-19 infections, including hospitalizations and death.

Benefits of a COVID-19 booster in pregnancy

    • Recently the World Health Organization recommended a COVID-19 booster during pregnancy if the last dose was over six months ago.
    • It is abundantly clear that COVID-19 infection in pregnancy carries considerable risk to the pregnant person and the fetus.

US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend AREXVY for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making

Retrieved on: 
Thursday, June 22, 2023
Research, Infectious Diseases, FDA, Seniors, Biotechnology, Health, Consumer, Pharmaceutical, Science, ACIP, GSK, The New England Journal of Medicine, US Foods, Respiratory syncytial virus vaccine, Diabetes, Vaccination, United States Department of Health and Human Services, Season, Chronic lung disease, DSM-IV codes, Multimedia, Morbidity and Mortality Weekly Report, CDC, Death, GSK plc, RSV, State, Patient, Risk, MMWR, Stockholm Environment Institute US Center, Kidney, Ageing, Disease, III, Food, Vaccine, Poultry farming

GSK plc (LSE/NYSE: GSK) today announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the use of AREXVY (respiratory syncytial virus vaccine, adjuvanted) in adults aged 60 and older using shared clinical decision making.

Key Points: 
  • GSK plc (LSE/NYSE: GSK) today announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the use of AREXVY (respiratory syncytial virus vaccine, adjuvanted) in adults aged 60 and older using shared clinical decision making.
  • Shared clinical decision making empowers patients in consultation with their healthcare providers to determine whether RSV vaccination is appropriate for them.
  • These data will be submitted to the US Food and Drug Administration (FDA) for review.
  • The ACIP recommendations will be forwarded to the director of the CDC and the US Department of Health and Human Services for review and approval.

Autism Learning Partners Launches Center-Based ABA Therapy for Individuals in Lincoln, Rhode Island

Retrieved on: 
Thursday, April 13, 2023
ABA, Learning, Communication, Speech, Spectrum, ALP, LINCOLN, BCBA, Morbidity and Mortality Weekly Report, LABA, Applied behavior analysis, Language, Disability studies, CDC, School, Behavior, ASD, MMWR, M.A, Diagnosis, Mobility, Hospital Insurance and Diagnostic Services Act, Residential care

LINCOLN, R.I., April 13, 2023 /PRNewswire-PRWeb/ -- Autism Learning Partners (ALP), a national leader that specializes in the treatment of autism and other developmental disabilities, is pleased to announce its in-state expansion with the addition of our first ABA therapy center in Lincoln, Rhode Island. ALP initiated this center-based extension in the greater Providence area in response to the need for quality center-based services. Services support families living in Bristol, Kent, Newport, Providence, and Washington County. ALP is committed to continuing collaborative efforts with schools, ancillary services and medical providers in the greater Providence area and steadfast in its dedication to providing resources to families.

Key Points: 
  • Autism Learning Partners (ALP), a national leader that specializes in the treatment of autism and other developmental disabilities, is pleased to announce its in-state expansion with the addition of our first ABA therapy center in Lincoln, Rhode Island.
  • ALP initiated this center-based extension in the greater Providence area in response to the need for quality center-based services.
  • LINCOLN, R.I., April 13, 2023 /PRNewswire-PRWeb/ -- Autism Learning Partners (ALP), a national leader that specializes in the treatment of autism and other developmental disabilities, is pleased to announce its in-state expansion with the addition of our first ABA therapy center in Lincoln, Rhode Island.
  • To learn more about Autism Learning Partners and its services, please visit http://www.AutismLearningPartners.com .

Playing Catch-Up: Hospitals Seek High-Tech Solutions to Meet Telehealth Demands

Retrieved on: 
Monday, October 24, 2022
Acumen, National Association Medical Staff Services, Morbidity and Mortality Weekly Report, Use, Digital technology, Communication, Sale, ICU, Life, Hospital, Bed, Cardiology, Patient, MMWR, MOME, Telehealth, Technology, Radiology, Telemetry, Disease, Economics, Decision-making, ARC, Vital signs, FDA, COVID-19, Medical device

WALTHAM, Mass., Oct. 24, 2022 /PRNewswire-PRWeb/ -- In 2020, the COVID-19 pandemic dramatically changed hospital operations. As facilities limited non-COVID care, medical providers turned to telehealth solutions to treat patients.(1) Patients and providers relied on a patchwork of videoconferencing systems, patient portals, and rudimentary home health equipment to manage non-emergency care. "Value-based care means flexibility in clinical capability," says The Virtual Telemetry Company, InfoBionic, CEO Stuart Long. "Portable telemetry for on-site use and remote telemetry for home use are the logical next steps in this era of virtual care. Telehealth is only growing in popularity and effectiveness. Now is the time for hospitals to augment their current telehealth practices with robust yet adaptable technology."

Key Points: 
  • Hospitals, providers, and patients all understand the need for high-tech, reliable monitoring that can go from hospital to home without compromising care.
  • As facilities limited non-COVID care, medical providers turned to telehealth solutions to treat patients.
  • Now is the time for hospitals to augment their current telehealth practices with robust yet adaptable technology."
  • Providers and healthcare facilities are racing to upgrade systems to use telehealth more effectively in the near future.

CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children

Retrieved on: 
Wednesday, June 22, 2022
Health, Consumer, Children, Baby, Maternity, Pharmaceutical, Biotechnology, MSD, Immunocompetence, Population, Department, Fever, Fatigue, Patent, Security (finance), COVID-19, Animal, Streptococcus, Conjugate vaccine, Vaccine, Streptococcus pneumoniae, Disease, 23F, MMWR, Irritability, PCV13, United States Department of Health and Human Services, Myalgia, U.S. Securities and Exchange Commission, MRK, ACIP, Research, LinkedIn, Private Securities Litigation Reform Act, Ageing, Vaccination, Merck & Co., YouTube, Allergy, News, SEC, Twitter, Anaphylaxis, Diphtheria, Apnea, Coronavirus, Instagram, CDC, Headache, NYSE, Vaccines for Children Program, Human services, Morbidity and Mortality Weekly Report, Somnolence, Pharmaceutical industry, Merck, Facebook

Additionally, the ACIP unanimously voted to include VAXNEUVANCE in the Vaccines for Children program.

Key Points: 
  • Additionally, the ACIP unanimously voted to include VAXNEUVANCE in the Vaccines for Children program.
  • VAXNEUVANCE is contraindicated for individuals with a severe allergic reaction (e.g., anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.
  • Serotypes 3, 22F and 33F are responsible for more than a quarter of all invasive pneumococcal disease cases in children.
  • Vaccination of premature infants should be based on the infants medical status and the potential benefits and possible risks.

BioMed Stocks On the Move: GeoVax Labs, Nova Mentis, SIGA and PharmaDrug; Life Sciences Leaders Report Latest Advances in Antiviral Vaccines, and Novel Therapeutics for Oncology, Glaucoma and Autism

Retrieved on: 
Monday, May 23, 2022
Psilocybin, PDUFA, Public health, EST, PEP, Method, Contract, Government, Substituted tryptamine, Monkeypox, United States Department of Defense, Interview, Autism, Esophageal cancer, Prostate cancer, SUPER, NDA, Health Canada, SIGA Technologies, SEC, Cancer, MMWR, Fragile X syndrome, News, Clinical trial, COVID-19, Patent, ASD, Pharmaceutics, CSE, Smallpox, CMO, CDC, Malaria, GLOBE, FXS, NOVA, GeoVax, Infection, Goal, Vaccine, Plasma protein binding, IV, Defense, Trial of the century, FDA, Autism spectrum, Biotechnology, Toxicity, DMT, Therapy, MVA, Toronto Institute of Pharmaceutical Technology, Wall Street, Cepharanthine, History, NASDAQ, OTC, NEXT, Intraocular pressure, Industry, Antigen, Glaucoma, BARDA, CEO, Pharmaceutical industry, Animal, Pension fund, MD

As the global pharma market suprasses $1.3 trillion dollars (Statista), emerging technologies and healthcare research innovations are unleashing new exponential growth opportunities.

Key Points: 
  • As the global pharma market suprasses $1.3 trillion dollars (Statista), emerging technologies and healthcare research innovations are unleashing new exponential growth opportunities.
  • As the biotech sector rebounds from cyclical lows, institutional investors are increasingly eyeing early-stage biotech stocks for upside potential delivering alpha.
  • However, developing vaccines against global public health threats such as malaria, is also part of our longer-term focus.
  • Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) CMO Marvin Hausman, M.D.

 Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older

Retrieved on: 
Tuesday, March 29, 2022
Health, FDA, Infectious Diseases, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Private Securities Litigation Reform Act, Risk, Elanco, Veni, vidi, vici, Pfizer–BioNTech COVID-19 vaccine, MedRxiv, Vaccine, Research, SEC, Publication, Disease, Twitter, COVID-19, UK Health Security Agency, Annual report, Marketing, Pediatrics, BioNTech, RNA transfection, U.S. Securities and Exchange Commission, Science, MMWR, BNT162, Immunotherapy, Clinical trial, Program, Dixons Carphone, Severe acute respiratory syndrome coronavirus 2, Awareness, Company, LinkedIn, Social Science Research Network, News, Hospital, Cancer, Regeneron Pharmaceuticals, Hoffmann-La Roche, Safety, Pierre Geneves, Facebook, Peer review, YouTube, Salvation Army Vision Network, Infection, Pharmaceutical industry, Online gambling, Delta, Omicron, Genentech, Pfizer, PFIZER: BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES, BIONTECH

In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer .

Key Points: 
  • In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer .
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.
  • BNT162b2 (PfizerBiontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design.

The Academy of Oncology Nurse & Patient Navigators Voices Support for Cancer Patient Infusions That Might Enhance Protection Against COVID-19

Retrieved on: 
Wednesday, February 16, 2022
Lynx, Korea Disease Control and Prevention Agency, Patient, Family, Quality of life, Cancer, Food, Health, Risk, CDC, Federation, Academy, Vaccine, RNA transfection, Nursing, Immunodeficiency, Kaiser Family Foundation, Therapy, Oncology, COVID-19 vaccine, Pharmacist, Center, Hematological Cancer Research Investment and Education Act, Treatment, Veni, vidi, vici, MMWR, Pharmacy, FDA, Hospital, Communication, Public health, Disease, Physician, COVID-19, Vaccination, Caregiver, Food and Drug Administration Amendments Act of 2007, Organization, Pharmaceutical industry, Medicine

We are writing you about the special needs of cancer patients and other immune compromised individuals during the COVID-19 pandemic.

Key Points: 
  • We are writing you about the special needs of cancer patients and other immune compromised individuals during the COVID-19 pandemic.
  • Patients with hematologic cancers, many cancer patients in treatment, and certain other cancer patients can offer their experience to underscore the challenges associated with COVID-19.
  • Cancer patients, because of their disease or the treatments for their disease, may be immune compromised.
  • About the Academy of Oncology Nurse & Patient Navigators, Inc. (AONN+)
    The Academy of Oncology Nurse & Patient Navigators, Inc. (AONN+), is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators.